Haleon Stock (NYSE:HLN)
Previous Close
$9.54
52W Range
$7.89 - $10.80
50D Avg
$9.52
200D Avg
$9.32
Market Cap
$43.14B
Avg Vol (3M)
$7.99M
Beta
0.24
Div Yield
$0.16 (1.66%)
HLN Company Profile
Haleon plc engages in the research and development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides therapeutic oral health, pain relief, respiratory health, digestive health, and other products, as well as vitamins, minerals, and supplements. Its portfolio of brands include Panadol, Voltaren, Advil, Otrivin, Theraflu, Sensodyne, Polident, parodontax, and Centrum. The company was formerly known as DRVW 2022 plc and changed its name to Haleon plc in February 2022. Haleon plc was incorporated in 2021 and is headquartered in Brentford, the United Kingdom.
HLN Performance
Peer Comparison
| Ticker | Company |
|---|---|
| HCM | HUTCHMED (China) Limited |
| TAK | Takeda Pharmaceutical Company Limited |
| EBS | Emergent BioSolutions Inc. |
| BHC | Bausch Health Companies Inc. |
| ESPR | Esperion Therapeutics, Inc. |
| ZTS | Zoetis Inc. |
| NBIX | Neurocrine Biosciences, Inc. |
| VTRS | Viatris Inc. |
| RDY | Dr. Reddy's Laboratories Limited |
| ELAN | Elanco Animal Health Incorporated |
| SIGA | SIGA Technologies, Inc. |
| TEVA | Teva Pharmaceutical Industries Limited |
| LNTH | Lantheus Holdings, Inc. |